- Research works
- 111 ▼ 3% vs 2013–17
- Citations
- 754 6.8 per fractional work
- Top-10% rate
- 13.3% record average 16.5%
- Open access
- 47% world 28%
Not ranked overall: Oblikue Consulting (Spain) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 9.2×. Every wedge is a field page.
- Economics, Econometrics and Finance 9.2×
- Immunology and Microbiology 6.2×
- Earth and Planetary Sciences 2.7×
- Medicine 1.9×
- Environmental Science 1.7×
- Business, Management and Accounting 1.3×
- Biochemistry, Genetics and Molecular Biology 1.2×
- Health Professions 1.1×
- Agricultural and Biological Sciences 0.9×
- Nursing 0.6×
- Neuroscience 0.5×
- Engineering 0.4×
- Materials Science 0.1×
- Social Sciences 0.0×
Who are the top researchers at Oblikue Consulting (Spain)?
Ranked on the composite score, Xavier Badía, Carlos Crespo and Max Brosa lead among researchers whose main affiliation is Oblikue Consulting (Spain).
- 1 Xavier Badía Spain · #1,255,929 worldwide 11 citations · 19 works
- 2 Carlos Crespo Spain · #1,437,425 worldwide 7 citations · 17 works
- 3 Max Brosa Spain · #1,558,139 worldwide 4 citations · 15 works
Which keywords describe research at Oblikue Consulting (Spain)?
By fractional works in all years, weighted toward what it does more of than the world: Quality of Life, Cost-effectiveness Analysis, Health Utility Measures, Pharmaceutical Industry, Drug Development Costs, Generic Drugs, Clinical Trials and Epidemiology.
- Liver Disease
- Health Outcomes
- Biopharmaceuticals
- Monoclonal Antibodies
- Health Care Costs
- Prophylaxis
- Clinical Guidelines
- Patient Engagement
- Clinical Outcomes
- Global Burden
- Cost of Care
- Heart Failure
- Clinical Practice Guidelines
- Cardiovascular Disease
- Guidelines
- Diagnosis
- Clinical Trials
- Drug Development Costs
- Pharmaceutical Industry
- Cost-effectiveness Analysis
- Quality of Life
- Health Utility Measures
- Epidemiology
- Generic Drugs
- Treatment
- Inflammation
- Medication Adherence
- Quality Improvement
- Innovation
- Adverse Drug Reactions
- Financial Toxicity
- Prognostic Factors
- Off-Label Drug Use
- Pediatric Pharmacokinetics
- Primary Care
- Choosing Wisely
- Low-Value Care
- Bioanalytical Methods
- Biosimilars
- Immunogenicity
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Quality of Life17▲ 11×9 topics
- Cost-effectiveness Analysis15▲ 178×1 topic
- Health Utility Measures15▲ 178×1 topic
- Pharmaceutical Industry10▲ 222×2 topics
- Epidemiology10▲ 2.2×37 topics
- Drug Development Costs9▲ 322×1 topic
- Generic Drugs9▲ 322×1 topic
- Clinical Trials6▲ 8.6×9 topics
- Treatment5▲ 3.8×12 topics
- Diagnosis4▲ 4.0×11 topics
- Inflammation4▲ 1.69×21 topics
- Guidelines3▲ 6.2×7 topics
- Medication Adherence3▲ 50×2 topics
- Cardiovascular Disease3▲ 2.5×13 topics
- Quality Improvement3▲ 13×5 topics
- Clinical Practice Guidelines3▲ 4.9×9 topics
- Innovation3▲ 2.9×6 topics
- Heart Failure3▲ 5.7×6 topics
- Adverse Drug Reactions3▲ 36×2 topics
- Cost of Care3▲ 125×1 topic
- Financial Toxicity3▲ 125×1 topic
- Global Burden3▲ 4.4×6 topics
- Prognostic Factors3▲ 5.1×7 topics
- Clinical Outcomes2▲ 11×4 topics
- Off-Label Drug Use2▲ 61×1 topic
- Patient Engagement2▲ 25×3 topics
- Pediatric Pharmacokinetics2▲ 61×1 topic
- Clinical Guidelines2▲ 7.0×5 topics
- Primary Care2▲ 5.2×4 topics
- Prophylaxis2▲ 14×4 topics
- Choosing Wisely2▲ 93×1 topic
- Health Care Costs2▲ 25×2 topics
- Low-Value Care2▲ 93×1 topic
- Monoclonal Antibodies2▲ 12×3 topics
- Bioanalytical Methods2▲ 113×1 topic
- Biopharmaceuticals2▲ 26×2 topics
- Biosimilars2▲ 113×1 topic
- Health Outcomes2▲ 7.3×4 topics
- Immunogenicity2▲ 34×2 topics
- Liver Disease2▲ 11×3 topics
Which research topics does Oblikue Consulting (Spain) publish most on?
By volume in 2022–2025: Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical studies and practices, Pharmaceutical Economics and Policy and Remote Sensing in Agriculture.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works
- 2 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 1 works
- 3 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 4 Remote Sensing in Agriculture Ecology 1 works
- 5 Educational and Organizational Development Organizational Behavior and Human Resource Management 0 works
- 6 Business, Innovation, and Economy Economics and Econometrics 0 works
- 7 Neutrophil, Myeloperoxidase and Oxidative Mechanisms Immunology 0 works
- 8 Healthcare cost, quality, practices General Health Professions 0 works
- 9 Hemophilia Treatment and Research Hematology 0 works
- 10 Cerebrovascular and genetic disorders Neurology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Oblikue Consulting (Spain)'s research output changed?
Output in 2018–2022 was 3% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Barcelona
- Universitat de Barcelona
- Universitat Politècnica de Catalunya
- Universitat Pompeu Fabra
- Hospital Clínic de Barcelona
- Vall d'Hebron Hospital Universitari
- Hospital de Sant Pau
- Universitat Oberta de Catalunya
- Institució Catalana de Recerca i Estudis Avançats
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.